Did you mean?

Ind-Swift Ltd dividend

Indifra Ltd dividend



Ind-Swift Ltd dividend

Ind-Swift Ltd dividend

stocks purchased

₹ 0.0 Cr

Volume transacted

stocks purchased

0.6 K

stocks traded


Ind-Swift Ltd




Last updated : FY 2023

Key Highlights

    The Dividend per Share of Ind-Swift Ltd is ₹ 0 as of 2023 .a1#The Dividend Payout of Ind-Swift Ltd changed from 0 % on March 2019 to 0 % on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#The Latest Trading Price of Ind-Swift Ltd is ₹ 20.9 as of 18 May 15:30 .a1#The Market Cap of Ind-Swift Ltd changed from ₹ 60.61 crore on March 2022 to ₹ 39.11 crore on March 2023 . This represents a CAGR of -19.67% over 2 years. a1#The Revenue of Ind-Swift Ltd changed from ₹ 96.18 crore to ₹ 181.82 crore over 8 quarters. This represents a CAGR of 37.49% a1#The EBITDA of Ind-Swift Ltd changed from ₹ 6.63 crore to ₹ 61.08 crore over 8 quarters. This represents a CAGR of 203.52% a1#The Net Profit of Ind-Swift Ltd changed from ₹ -15.44 crore to ₹ 37.54 crore over 8 quarters. This represents a CAGR of NaN% a1#

Open Demat Account

Lead form image


50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

Share Price Vs Dividend Yield


Fundamental Metrics

Market Cap

112 Cr



P/E Ratio (TTM) *


P/B Ratio (TTM) *








Dividend Yield *




Dividend Payout *


Ann.Dividend % *


* All values are consolidated

* All values are consolidated


Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Mar '190
Mar '200
Mar '210
Mar '220
Mar '230

* All values are a in %

Dividend per Share (DPS) Over Time



Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.

Dividend Yield Comparison With Top Peers





* All values are in %

Net Profit Vs Dividend Per Share


Ind-Swift Ltd





stock direction

Last updated : 18 May 15:30

SWOT Analysis Of Ind-Swift Ltd













Dividend Overview for Ind-Swift Ltd

  • Ind-Swift Ltd, boasts of a market capitalization of Rs 113 Cr., with a share price of Rs 20.90 as of 18 May 15:30. While all stocks don't consistently pay dividends, Ind-Swift Ltd rewarded its shareholders, distributing 0.0 % for the full year.
  • In the year ending 2022, Ind-Swift Ltd declared a dividend of Rs 0, resulting in a dividend yield of 0.0% Assessing its dividend-paying capacity and valuation is crucial to determine its suitability as a dividend stock.
  • During the year ending 2023, Ind-Swift Ltd recorded revenues of Rs 502 Cr, with a trailing EBITDA Margin of 21.2% and net-profit of Rs 14 Cr

Overview of Dividend

Types of Dividend

Special Dividend

A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.

Preferred Dividend

A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.

Interim Dividend

Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.

Final Dividend

A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:


Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Mar '2261
Mar '2339

* All values are a in crore


Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Jun '2296
Sep '22105
Dec '22110
Mar '22173
Jun '23154
Sep '23119
Dec '23105
Mar '23182

* All values are a in crore


EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Jun '227
Sep '2212
Dec '2221
Mar '2275
Jun '2324
Sep '2314
Dec '237
Mar '2361

* All values are a in crore


Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Jun '22-15
Sep '22-11
Dec '22-1
Mar '2253
Jun '232
Sep '23-11
Dec '23-15
Mar '2338

* All values are a in crore

About Ind-Swift Ltd

About Ind-Swift Ltd

    Ind-Swift Ltd (ISL) is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of pharmaceutical finished dosage. The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables. The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty. Ind-Swift Ltd was incorporated in the year 1986. In the year 1991, the company set up a manufacturing facility for injectables and eye/ear drops. In the year 1995, they incorporated Ind-Swift Laboratories Ltd for initiating a backward integration into the manufacturing of APIs and advanced intermediates. In the year 1997, the company commissioned a multipurpose plant with five independent blocks erected as per US FDA standards, designed by Quara, Switzerland. In addition, they launched a Marketing Division with the name Ind-Swift Health Care. In the year 2000, the company launched Super Specialty Division, which is focusing on Cardiology and Diabetology segments. In the year 2001, they launched Pioglitazone and Candesartan, in which the company is the second to launch this product in India. In addition, they launched Institution/Hospital Division. In the year 2003, the company launched another division by the name Ind-Swift Biosciences. They entered into formulations export to six countries and filed patent in US for Clarithromycin. In the year 2004, the company launched Mukur Division with focus on ophthalmology, neuropsychiatry and ENT. They launched Launched Nitazoxanide, an antidiarrhoeal drug, first time in India after successful clinical trials. In addition, they launched another division by the name Resurgence catering to the Anesthesiology and Oncology segments. The company opened first overseas office in New Jersey, USA During the year 2004-05, the company launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia. They commenced commercial production in their new formulation facility at Jammu, J&K. During the year 2005-06, the company introduced various new product ranges in the domestic market through their nine marketing divisions. The new product launches included the launch of a unique combination of the Quinoline derivative, anti-diarrheal and anti-bacterial drug that was launched for the first time in India after completion of the successful clinical trials. They also launched the new marketing division namely Institutions & Hospitals division to look after the institutional sales. During the year, the company commissioned three new state of the art finished dosages facility at; Samba in Jammu & Kashmir; 100% EOU at Jawaharpur and an internationally benchmarked plant at Baddi in Himachal Pradesh. During the year 2006-07, the company developed and launched 65 new products and line extension. They launched their product in Kenya and Senegal. They also launched three new marketing division to focus on marketing of products for personal healthcare, veterinary and manufacturing and marketing of products for international companies. During the year, the company entered into licensing agreements with number of international Pharma companies for out licensing the technology of their patented products, Clarithromycin. They received approval of the Drug Authorities of Uganda and Tanzania, which will pave the way for the supply of their drugs in these countries. During the year 2007-08, the company's manufacturing unit at Parwanoo was upgraded as per WHO standards. The company's Global Business unit at Derabassi got MHRA & TGA approval. The manufacturing unit at Baddi received WHO GMP certification for tablet/SVP/Liquid manufacturing. In August 2007, the company commissioned a manufacturing facility at the same tax exempted zone and green plains of Baddi. This facility is for soft Gelatin Encapsultation with an annual capacity of 36 crore. In December 2007, they launched their new division 'Diagnozis' dealing in medical equipments & devices. The company also launched animal health care, which is absolutely a new concept with outsourced marketing. Company launched a new marketing division 'NOVA' with special focus on ophthalmology, ENT and Dermatology in 2009-10. During 2010-11, the Company launched six divisions viz GENERIC, ONCRIT, MEGASWIFT, GYNOSWIFT, Q-DEN and CARDIA SWIFT. Apart from this, it launched new product range in all the new divisions including monopolistic products. During 2012, the Company diversified into the Dairy Business by launching a new division, which marketed under the brand name 'All Natural'. In 2021, company established a separate OTC division and launched 2 products being, Stevia (natural sweetener) and Hangover.

Ind-Swift Ltd News Hub


Ind-Swift declare Quarterly Result

Ind-Swift will hold a meeting of the Board of Directors of the Company on 14 May 2024. Pow...

Read more

02 May 2024 16:24


Ind-Swift Ltd leads losers in 'B' group

Sadbhav Engineering Ltd, DCM Nouvelle Ltd, MRO-TEK Realty Ltd and Suncare Traders Ltd are ...

Read more

10 Apr 2024 14:45


Ind-Swift revises board meeting date

Ind-Swift has revised the meeting of the Board of Directors which was scheduled to be held...

Read more

08 Feb 2024 12:01


Ind-Swift to conduct board meeting

Ind-Swift will hold a meeting of the Board of Directors of the Company on 13 February 2024...

Read more

30 Jan 2024 14:45


Ind-Swift to announce Quarterly Result

Ind-Swift will hold a meeting of the Board of Directors of the Company on 9 November 2023....

Read more

31 Oct 2023 17:17


Ind-Swift schedules EGM

Ind-Swift announced that an Extra Ordinary General Meeting (EGM) of the Company will be he...

Read more

13 Sep 2023 12:14

FAQs for dividends of Ind-Swift Ltd

What is the current market price of Ind-Swift Ltd Ltd as of May 18, 2024?

The current market price of Ind-Swift Ltd Ltd stands at 20.9 per share.

What dividend did Ind-Swift Ltd declare in the last fiscal year?

In the last fiscal year, Ind-Swift Ltd declared a dividend totaling ₹0.0.

What is the most recent dividend declared by Ind-Swift Ltd?

Ind-Swift Ltd recently declared a dividend of 0.0 in the latest quarter

How many times has Ind-Swift Ltd declared dividends in the current fiscal year

Ind-Swift Ltd has declared dividends 4 times totaling ₹0 in the current fiscal year (FY2023-2024).

How many times did Ind-Swift Ltd declare dividends in the previous fiscal year?

In the previous fiscal year (FY2022-2023), Ind-Swift Ltd declared dividends 4 times totaling ₹0.
up arrow

Unlimited trading at just

Rs. 399

Rs. 199